Comparison
Berberine vs BPC-157
Side-by-side of Berberine and BPC-157. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Berberine
Berberine supplement guide: 1500 mg/day lowers fasting glucose and HbA1c, AMPK activation, metformin parity in RCTs, dihydroberberine absorption.
BPC-157
BPC-157 peptide profile: pentadecapeptide body protection compound 157. Preclinical data on tendon, gut healing, recovery. No human RCTs as of 2026.
Effects at a glance
Berberine
- •Lowers HbA1c by ~0.7% versus placebo at 1500 mg/day across 27-trial meta-analysis (Lan 2015)
- •Roughly comparable to metformin on fasting glucose and HbA1c in small head-to-head RCTs (Yin 2008)
- •Reduces LDL cholesterol 10-20% and triglycerides 15-25% via PCSK9 inhibition
- •Activates AMPK, the cellular energy sensor that drives insulin-independent glucose uptake
- •Oral bioavailability under 1%; dihydroberberine is the higher-absorption alternative at lower doses
- •GI side effects affect 10-30% at 1500 mg/day; split dosing with meals reduces incidence
BPC-157
- •Preclinical models show accelerated tendon-to-bone and ligament healing after surgical or chemical injury
- •Rodent studies report mucosal protection and faster recovery from NSAID-induced and colitis-induced gut damage
- •Anecdotal human protocols use 250 to 500 mcg twice daily subcutaneously near the injury site
- •No completed phase II or III human RCTs as of 2026, so efficacy and long-term safety remain unestablished
- •Banned by WADA since 2022 under the S0 non-approved substances category for competitive athletes
- •Theoretical angiogenic concern means avoidance is prudent in active malignancy until human data exists
Side-by-side
| Attribute | Berberine | BPC-157 |
|---|---|---|
| Category | natural | peptide |
| Also known as | berberine HCl, berberine hydrochloride | Body Protection Compound-157, Pentadecapeptide BPC-157 |
| Half-life (hr) ↗ | 3 | 4 |
| Typical dose (mg) ↗ | 1500 | 0.25 |
| Dosing frequency | 3x daily with meals | daily (anecdotal protocols) |
| Routes | oral | subcutaneous, intramuscular, oral |
| Onset (hr) | 2 | - |
| Peak (hr) | 3 | - |
| Molecular weight | 336.36 | - |
| Molecular formula | C20H18NO4+ | C62H98N16O22 |
| Mechanism | Activates AMP-activated protein kinase (AMPK), suppressing hepatic gluconeogenesis and lipogenesis while increasing peripheral glucose uptake. Inhibits PCSK9 transcription, modulates bile acid signaling, and shifts gut microbiome composition. | Proposed upregulation of VEGFR2 and nitric oxide pathways, modulation of growth-hormone receptor expression, and stabilization of gut-brain axis signaling. Mechanism remains largely preclinical. |
| Legal status | Dietary supplement (US, EU, UK, Canada); Rx in some Asian jurisdictions | Not FDA approved; research-use-only grey market; banned by WADA (2022) |
| WADA status | allowed | banned |
| DEA / Rx | Not scheduled | Not FDA approved; not scheduled; research-chemical status |
| Pregnancy | Contraindicated (kernicterus risk in neonates) | Insufficient data |
| CAS | 2086-83-1 | 137525-51-0 |
| PubChem CID | 2353 | 9941957 |
| Wikidata | Q411435 | Q4835418 |
Safety profile
Berberine
Common side effects
- constipation
- diarrhea
- abdominal cramping
- flatulence
- nausea
Contraindications
- pregnancy
- lactation
- neonatal jaundice
- severe liver disease
Interactions
- metformin: additive HbA1c reduction; additive GI side effects(moderate)
- insulin or sulfonylureas: additive hypoglycemia risk; dose adjustment may be required(major)
- statins (simvastatin, atorvastatin): CYP3A4 inhibition raises statin plasma levels(moderate)
- cyclosporine: raises cyclosporine levels through CYP3A4 and P-gp inhibition(major)
- calcium channel blockers (amlodipine): elevated plasma levels via CYP3A4 inhibition(moderate)
BPC-157
Common side effects
- injection-site irritation
- nausea
- headache (anecdotal)
Contraindications
- pregnancy
- active malignancy (theoretical angiogenic concern)
- no established safety profile in humans
Which Should You Take?
Berberine comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. BPC-157 is the right call when one of the conditionals below applies.
- → If your priority is metabolic health and glucose control, pick Berberine.
- → If your priority is healthspan extension, pick Berberine.
- → If your priority is post-training recovery, pick BPC-157.
- → If your priority is gut barrier and microbiome health, pick BPC-157.
Edge case: If you want to avoid research-only / gray-market sourcing, Berberine is the more accessible choice.
Default choice: Berberine. Lower friction to source, and broader goal coverage. Reach for BPC-157 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Berberine and BPC-157?
Berberine and BPC-157 differ in category (natural vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Berberine or BPC-157?
Berberine half-life is 3 hours; BPC-157 half-life is 4 hours.
Can you stack Berberine with BPC-157?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper